DCPH Stock

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Japan's Ono Pharmaceutical Co announced on Tuesday that its acquisition of Deciphera Pharmaceuticals for $2.4 billion is the initial move in its expansion into the U.S. and European markets.

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) surged 75% today following ONO Pharmaceutical's (TYO: 4528) announcement of a $2.4 billion acquisition. Deciphera Pharmaceuticals stock is now worth $25.60 per share.

Deciphera Pharmaceuticals (NASDAQ: DCPH) shares are increasing today following the announcement of a $2.4 billion acquisition by ONO Pharmaceutical. Under the agreement, ONO Pharmaceutical will purchase Deciphera Pharmaceuticals for $25.60 per share in cash.

Deciphera Pharmaceuticals is being acquired by ONO Pharmaceutical of Japan in a $2.4 billion deal.

Deciphera Pharmaceuticals announced on Monday that ONO Pharmaceutical Co will purchase the company for $2.4 billion in cash.

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

The consensus price target hints at a 48.5% upside potential for Deciphera Pharmaceuticals, Inc. (DCPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 59.6% in Deciphera Pharmaceuticals, Inc. (DCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.